Product Description
AM-006 is being developed by Affamed Therapeutics (HK) Limited/ Fuji Chemical Industries/Shanghai Affamed Medical Technology for the treatment of early Parkinson's Disease. (Sourced from: https://www.affamed.com/press-releases-25)
Mechanisms of Action: DR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AffamedTherapeutics(HK)Limited/FujiChemicalIndustriesCo.,Ltd./Shanghai Aimai Medical Technology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20222485 |
CTR20222485 | P1 |
Completed |
Parkinson's Disease |
2023-03-24 |
2025-04-29 |
||
CTR20212118 |
CTR20212118 | P2 |
Not yet recruiting |
Parkinson's Disease |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/27/2021 |
News Article |
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease |
|
03/29/2021 |
News Article |
Silver Wolf Announces Recent Work and Results of Select Grab Samples from The Ana Maria Project That Show Gold and Silver Mineralization |
|
01/26/2021 |
News Article |
Austral Gold Extends Amancaya High Grade to Depth |